Vor Biopharma Inc. (VOR) News
Filter VOR News Items
VOR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VOR News Highlights
- VOR's 30 day story count now stands at 2.
- Over the past 22 days, the trend for VOR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about VOR are BIO and NOV.
Latest VOR News From Around the Web
Below are the latest news stories about VOR BIOPHARMA INC that investors may wish to consider to help them evaluate VOR as an investment opportunity.
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of November 29, 2023 the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 22,875 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 34,313 shares of Vor Bio’s common stock to four newly hired employees. The foregoing s |
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² ConferencePrimary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor Bio’s approachConference call today, November 9 at 4:30 PM ET CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label |
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company UpdateNext trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023 Dec 9-12 CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update. “We look forward to imminent data releases b |
Vor Bio to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Stifel 2023 Healthcare ConferenceFireside Chat: Tuesday, November 14, 2023 at 3:35 pm ET Location: Lotte New York Palace Hotel, New York, NY A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com. 6th Annual Evercore ISI |
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T PlatformThree oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Hematologic Malignancies Program in the Division of Oncology at Children's Hospital of Philadelphia, to discuss abstracts today, November 2, at 9.30 AM ET. CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, toda |
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company UpdateNext trem-cel clinical data update expected by year-end 2023VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiationSecured non-exclusive license to Cas9 gene-edited HSCs CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2023, and provided a business update. “We are pleased with the progress we have made during the q |
Vor Bio's Trem-cel Shows Early Encouraging Data In Leukemia PatientsVor Biopharma Inc (NASDAQ: VOR) presented updated data from patients treated in the VBP101 Phase 1/2a study of trem-cel (formerly VOR33) in acute myeloid leukemia patients. The time for neutrophil engraftment in all five patients treated with trem-cel (10-11 days) was similar to unedited transplants. All patients achieved high levels of myeloid donor chimerism by day 28. After achieving timely neutrophil engraftment and platelet recovery, patient 2 experienced secondary graft failure coincident |
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s PlatformPatients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust enrollment; additional data updates expected by year-end 2023.U.S. FDA clears VCAR33ALLO IND.Conference call scheduled for today, June 9 at 8:30am ET. CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patien |
Vor Bio to Participate in the Goldman Sachs Healthcare ConferenceCAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman Sachs 44th Annual Global Healthcare Conference. Goldman Sachs 44th Annual Global Healthcare ConferenceFireside Chat: Monday, June 12, 2023 at 8:00am PTLocation: Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA A live webcast and archived replay of the fireside chat will be available on the |